{"id":"W2047199620","doi":"10.1111/dom.12391","title":"Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes","year":2014,"lang":"en","type":"article","venue":"Diabetes Obesity and Metabolism","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Placebo; Tolerability; Pioglitazone; Medicine; Type 2 diabetes; Randomized controlled trial; Clinical endpoint; Internal medicine; Diabetes mellitus; Adverse effect; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003750014,0.001427251,0.003706922,0.0005979343,0.0004609044,0.0008457332,0.001041106,0.002373963,0.006346019],"category_scores_gemma":[0.00368821,0.0008355742,0.001995293,0.0004669382,0.001223281,0.0009458101,0.0004172603,0.003012646,0.0008052564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005776085,"about_ca_system_score_gemma":0.0009346121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009960429,"about_ca_topic_score_gemma":0.001909598,"domain_scores_codex":[0.9981455,0.001266323,0.0001435955,0.000202911,0.0001222022,0.0001195079],"domain_scores_gemma":[0.9972968,0.001226383,0.000534586,0.0002554896,0.0001340896,0.000552638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873288,0.002802205,0.0002045636,0.0002561876,0.0006473919,0.00001931585,0.0000181613,0.00008878422,0.00156037,0.00004064493,0.0001932598,0.00684046],"study_design_scores_gemma":[0.9756657,0.02325804,0.0004461492,0.000009938765,0.0002058474,0.00001047581,0.000003887247,0.0001054216,0.0001423598,0.00002613038,0.0001211371,0.000004890695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831318,0.008065658,0.0009371615,0.001011,0.0009394863,0.003105958,0.001074853,0.0001624795,0.001571588],"genre_scores_gemma":[0.9851511,0.003312298,0.002674698,0.001308215,0.0008916294,0.00328625,0.001223744,0.00003194753,0.002120205],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006346019,"threshold_uncertainty_score":0.02122957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01646030076962952,"score_gpt":0.2518779144821535,"score_spread":0.235417613712524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}